LENZ Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 19, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 19, 2025
LENZ$4.10-4.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
| Index to Consolidated Financial Statements | |
|---|---|
| Report of Independent Registered Accounting Firm (PCAOB ID No. 42) | 99 |
| Consolidated Balance Sheets | 100 |
| Consolidated Statements of Operations And Comprehensive Loss | 102 |
| Consolidated Statements of Convertible Preferred and Common Stock and Stockholders’ Equity (Deficit) | 103 |
| Consolidated Statements of Cash Flows | 105 |
| Notes to Consolidated Financial Statements | 106 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.